Incidence, Stage, Treatment, and Survival of Noncardia Gastric Cancer
JAMA Network Open · 21.08.2023 · 6 (8) · e2330018
DOI: 10.1001/jamanetworkopen.2023.30018 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 21.08.2023. Verfasst von Merel J M van Velzen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Stomach Neoplasms, Neoplasms, Second Primary, Adenocarcinoma. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Gastric cancer is the fifth most common cancer worldwide, and investigating its incidence, characteristics, treatment, and outcomes over the past decades can help in selecting clinical strategies and future research directions.
Objective
To analyze the trends in incidence, staging, and treatment of gastric cancer. Design, Setting, and Participants This nationwide, population-based cohort study included patients diagnosed with noncardia gastric cancer (NCGC) between 1989 and 2021 in the Netherlands. Main Outcomes and Measures Differences in tumor characteristics, treatment, and survival were analyzed per fixed time periods (1989-1993, 1994-1998, 1999-2003, 2004-2008, 2009-2013, 2014-2018, and 2019-2021).
Results
In total, 47 014 patients (median [IQR] age, 73 [64-80] years; 28 032 [60%] male patients) were identified with mostly adenocarcinomas of the antrum region (when location was known). Age-standardized incidence decreased from 20.3 to 6.1 per 100 000 person-years between 1989 and 2021. During the study period, unknown T and N stages were recorded less frequently, and metastatic disease was diagnosed more frequently (1989-1993: 2633 of 9493 patients [28%]; 2019-2021: 1503 of 3200 patients [47%] in 2019-2021). Over time, fewer patients with metastatic disease underwent surgery with or without other treatment modalities (68% in 1989-1993 vs 64% in 2019-2021), and palliative chemotherapy in metastatic NCGC increased from 9% to 40%. For patients with nonmetastatic disease, 5-year relative survival improved from 28% (95% CI, 26.5%-29.2%) to 36% (95% CI, 33.5%-37.6%) between 1989 and 2021. For patients with nonmetastatic disease undergoing a resection, 5-year survival increased from 40% (95% CI, 38.3%-41.8%) to 51% (95% CI, 47.9%-53.3%). For patients with metastatic disease, 1-year relative survival increased from 10% (95% CI, 8.7%-11.1%) to 19% (95% CI, 17.2%-21.6%), but 3-year relative survival remained poor at 5% (95% CI, 3.6%-7.5%). Conclusions and Relevance In this nationwide cohort study involving 47 014 patients diagnosed with NCGC (1989-2021), the results showed a decrease in incidence, more accurate staging, a shift in treatment modalities, and improved patient survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
- Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.
- Department of Surgery, Catharina Hospital, Eindhoven, Netherlands.
- Department of Surgery, Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam, Netherlands.
- Department of Gastroenterology and Hepatology, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, the Netherlands.
- Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Zitieren
APA
van Velzen, M. J. M., Braemer, M., Nieuwenhuijzen, G. A. P., van Sandick, J. W., Siersema, P. D., Ruurda, J. P., Verheij, M., Spaander, M. C. W., Beerepoot, L. V., Haj Mohammad, N., van Laarhoven, H. W. M., & Verhoeven, R. H. A. (2023). Incidence, Stage, Treatment, and Survival of Noncardia Gastric Cancer. JAMA Network Open, 6(8), e2330018. https://doi.org/10.1001/jamanetworkopen.2023.30018
Vancouver
van Velzen MJM, Braemer M, Nieuwenhuijzen GAP, van Sandick JW, Siersema PD, Ruurda JP, et al. Incidence, Stage, Treatment, and Survival of Noncardia Gastric Cancer. JAMA Network Open. 2023;6(8):e2330018. doi:10.1001/jamanetworkopen.2023.30018
BibTeX
@article{vanVelzen2023,
author = {van Velzen, Merel J M and Braemer, Michelle and Nieuwenhuijzen, Grard A P and van Sandick, Johanna W and Siersema, Peter D and Ruurda, Jelle P and Verheij, Marcel and Spaander, Manon C W and Beerepoot, Laurens V and Haj Mohammad, Nadia and van Laarhoven, Hanneke W M and Verhoeven, Rob H A},
title = {Incidence, Stage, Treatment, and Survival of Noncardia Gastric Cancer},
journal = {JAMA Network Open},
year = {2023},
volume = {6},
number = {8},
pages = {e2330018},
doi = {10.1001/jamanetworkopen.2023.30018}
}
EUVIMED